Anlotinib Clinical Trials
20 recruitingDrug
Phase 215Phase 33Phase 12Not Applicable2Phase 41
Showing 1–20 of 20 trials
Recruiting
Phase 3
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
Whole-Brain Radiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences134 enrolled1 locationNCT07443397
Recruiting
Phase 2Phase 3
Anlotinib Capsules in the Treatment for IPF/PF-ILDs
Interstitial Lung Diseases
First Affiliated Hospital of Wenzhou Medical University30 enrolled1 locationNCT05828953
Recruiting
Phase 2
A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
Breast Cancer
Zhejiang Cancer Hospital118 enrolled1 locationNCT07330544
Recruiting
Phase 2
To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital64 enrolled1 locationNCT06352008
Recruiting
Phase 1Phase 2
Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
Craniopharyngiomas
Nanfang Hospital, Southern Medical University57 enrolled1 locationNCT06970145
Recruiting
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Breast CancerBreast NeoplasmBreast Tumors
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Not Applicable
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
Small Cell Lung Cancer Recurrent
Fudan University39 enrolled1 locationNCT06258642
Recruiting
Phase 2
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
NSCLC Stage IV
Fudan University105 enrolled1 locationNCT04136535
Recruiting
Phase 2
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
SafetyLocally Advanced Non-Small Cell Lung CancerThoracic Radiotherapy
JIANYANG WANG44 enrolled1 locationNCT07037680
Recruiting
Phase 2
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Biliary Tract CancerCholangiocarcinomaGall Bladder Cancer+1 more
First Affiliated Hospital of Zhejiang University60 enrolled1 locationNCT07025174
Recruiting
Phase 2
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
Nasopharyngeal Carcinoma
Sun Yat-sen University47 enrolled1 locationNCT06851247
Recruiting
Phase 2
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Solid TumorPrecision Medicine
Tianjin Medical University Second Hospital300 enrolled1 locationNCT06739395
Recruiting
Phase 2
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
Locally Advanced Thyroid Gland Carcinoma
West China Hospital75 enrolled1 locationNCT06482086
Recruiting
Phase 1
Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
Breast Cancer
Fudan University42 enrolled1 locationNCT06331169
Recruiting
Phase 4
Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma
Soft Tissue SarcomaRadiotherapyDoxorubicin
Guangdong Provincial People's Hospital39 enrolled2 locationsNCT06506838
Recruiting
Phase 2
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
Metastatic Colorectal Cancer
Fudan University44 enrolled1 locationNCT05229003
Recruiting
Phase 2Phase 3
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital1,200 enrolled1 locationNCT04322617
Recruiting
Phase 2
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
Cervical Cancer
Zhongnan Hospital35 enrolled1 locationNCT05817214
Recruiting
Not Applicable
The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study
Ningbo Medical Center Lihuili Hospital30 enrolled1 locationNCT06188650
Recruiting
Phase 2
Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer
Pancreatic Adenocarcinoma Metastatic
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School177 enrolled1 locationNCT06051851